Share

March 10, 2015; 84 (10) Editorial

Andiamo! Moving forward with autologous hematopoietic transplantation for highly active MS

Paolo A. Muraro
First published February 11, 2015, DOI: https://doi.org/10.1212/WNL.0000000000001347
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
195

Share

Article Information

vol. 84 no. 10 968-969
DOI: 
https://doi.org/10.1212/WNL.0000000000001347
PubMed: 
25672922
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published February 11, 2015.

Article Versions

Copyright & Usage: 
© 2015 American Academy of Neurology

Author Disclosures

    1. Paolo A. Muraro, MD, PhD
  1. Paolo A. Muraro, MD, PhD
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Guest Editor, PLOS Medicine

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. Funder: Medical Research Council Type of grant: Patient Research Cohort Initiative Title: Rapidly evolving multiple sclerosis: opening the window of therapeutic opportunity Duration: 3 years PI: Muraro Co-applicants: Dr J Chataway, Professor G Giovannoni, Dr O Malik, Dr R Nicholas, Professor R Reynolds, Dr K Schmierer and Dr A Waldman Status: awarded 5.6.08 Starting date: 31/3/09 Reference number: G0800679

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Funder: UK Multiple Sclerosis Society / UK Stem Cell Foundation Type of grant: Collaborative Project Grant Title: A phase II trial of autologous mesenchymal stem cell transplantation in highly active multiple sclerosis ? Duration: 3 years PI: Muraro Co-applicants: Chandran, Dazzi, Miller, Nicholas Collaborators: Malik, Scott, Lowdell Status: Awarded April 2011 Reference number: Funder: UK Multiple Sclerosis Society Type of grant: Project Grant Title: Immunological mechanisms of autologous hematopoietic stem cell transplantation for treatment of severe multiple sclerosis Duration: 3 years PI: Muraro Co-applicants: Prof D Altmann Status: Awarded September 2010 Reference number: 938/10 Funder: Italian Multiple Sclerosis Foundation (FISM) Type of grant: Project Grant Title: Functional relevance of haematopoietic stem cell mobilisation following therapeutic alpha 4-integrin blockade in multiple sclerosis Duration: 2 years PI: Muraro Collaborators: Nicholas, Malik, Dazzi, Mattoscio Status: Awarded January 2011 Funder: Italian Multiple Sclerosis Foundation (FISM) Type of grant: Research grant Title: Identification of early prognostic factors affecting the long-term outcome in MS Proposed duration: 2 years PI: Muraro Status: awarded 12.12.08 Starting date: 1/4/09

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Division of Brain Sciences, Department of Medicine, Imperial College London, UK.
  1. Correspondence to Dr. Muraro: p.muraro{at}imperial.ac.uk
View Full Text

Article usage

Article usage: February 2015 to January 2021

AbstractFullPdfSource
Feb 2015439053Highwire
Mar 20154994565Highwire
Apr 2015771117Highwire
May 20155487Highwire
Jun 20154431Highwire
Jul 20154751Highwire
Aug 20153123Highwire
Sep 20154546Highwire
Oct 20151824Highwire
Nov 20151812Highwire
Dec 20154211Highwire
Jan 20163454Highwire
Feb 20161843Highwire
Mar 20162512Highwire
Apr 20162401Highwire
May 2016611Highwire
Jun 20162021Highwire
Jul 20161200Highwire
Aug 20161511Highwire
Sep 20161600Highwire
Oct 20162921Highwire
Nov 20161902Highwire
Dec 20161410Highwire
Jan 20172711Highwire
Feb 20171310Highwire
Mar 20172101Highwire
Apr 20172000Highwire
May 20171810Highwire
Jun 20171501Highwire
Jul 20171521Highwire
Aug 20171600Highwire
Sep 2017900Highwire
Oct 20171111Highwire
Nov 20171701Highwire
Dec 20171011Highwire
Jan 2018901Highwire
Feb 20181410Highwire
Mar 20182701Highwire
Apr 20183200Highwire
May 20182511Highwire
Jun 20184421Highwire
Jul 20182400Highwire
Aug 20181800Highwire
Sep 2018800Highwire
Oct 20181411Highwire
Nov 2018900Highwire
Dec 20181800Highwire
Jan 20191101Highwire
Feb 2019400Highwire
Mar 20191200Highwire
Apr 20193210Highwire
May 20191420Highwire
Jun 2019501Highwire
Jul 20191000Highwire
Aug 2019600Highwire
Sep 2019200Highwire
Oct 20191101Highwire
Nov 20191111Highwire
Dec 2019600Highwire
Jan 20201100Highwire
Feb 2020400Highwire
Mar 20201300Highwire
Apr 2020500Highwire
May 2020200Highwire
Jun 2020500Highwire
Jul 2020300Highwire
Aug 2020800Highwire
Sep 2020600Highwire
Oct 20201501Highwire
Nov 2020911Highwire
Dec 20201400Highwire
Jan 2021601Highwire

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me